Advanced search
Publication Cover
OncoTargets and Therapy Volume 10, 2017 - Issue
Submit an article Journal homepage
55
Views
10
CrossRef citations to date
0
Altmetric
Original Research

Intensity-modulated radiotherapy plus nimotuzumab with or without concurrent chemotherapy for patients with locally advanced nasopharyngeal carcinoma

Jianfeng Huang1 Department of Radiation Oncology, Affiliated Hospital of Jiangnan University
,
Qinzhou Zou1 Department of Radiation Oncology, Affiliated Hospital of Jiangnan University
,
Danqi Qian1 Department of Radiation Oncology, Affiliated Hospital of Jiangnan University
,
Leyuan Zhou1 Department of Radiation Oncology, Affiliated Hospital of Jiangnan University
,
Bo Yang1 Department of Radiation Oncology, Affiliated Hospital of Jiangnan University
,
Jianjun Chu1 Department of Radiation Oncology, Affiliated Hospital of Jiangnan University
,
Qingfeng Pang2 Department of Epidemiology, Wuxi Medical School of Jiangnan University, Wuxi, Jiangsu, People’s Republic of China
,
Kewei Wang2 Department of Epidemiology, Wuxi Medical School of Jiangnan University, Wuxi, Jiangsu, People’s Republic of ChinaCorrespondence[email protected]
&
Fuzheng Zhang1 Department of Radiation Oncology, Affiliated Hospital of Jiangnan UniversityCorrespondence[email protected]
 show all
Pages 5835-5841 | Published online: 08 Dec 2017

Citations (10)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Jianfeng Huang, Xiaopeng Yuan, Qingfeng Pang, Haowen Zhang, Jiahua Yu, Bo Yang, Leyuan Zhou, Fuzheng Zhang & Fenju Liu. (2018) Radiosensitivity enhancement by combined treatment of nimotuzumab and celecoxib on nasopharyngeal carcinoma cells. Drug Design, Development and Therapy 12, pages 2223-2231.
Read now

Articles from other publishers (9)

朋菲 张. (2022) Clinical Observation of Induction Chemotherapy Followed by Nimotuzumab and Radiotherapy in the Treatment of Patients with Locally Advanced Nasopharyngeal Carcinoma. Advances in Clinical Medicine 12:01, pages 425-430.
Crossref
Renba Liang, Liu Yang & Xiaodong Zhu. (2021) Nimotuzumab, an Anti-EGFR Monoclonal Antibody, in the Treatment of Nasopharyngeal Carcinoma. Cancer Control 28, pages 107327482198930.
Crossref
Xishan Chen, Renba Liang & Xiaodong Zhu. (2020) Anti-EGFR therapies in nasopharyngeal carcinoma. Biomedicine & Pharmacotherapy 131, pages 110649.
Crossref
Yuanbo Kang, Weihan He, Caiping Ren, Jincheng Qiao, Qiuyong Guo, Jingyu Hu, Hongjuan Xu, Xingjun Jiang & Lei Wang. (2020) Advances in targeted therapy mainly based on signal pathways for nasopharyngeal carcinoma. Signal Transduction and Targeted Therapy 5:1.
Crossref
Sai-xi Bai, Ruo-rong Zhang, Wang-hua Chen, Hong-min Dong, Gang Wang, Xiao-kai Li & Wenling Wang. (2020) Clinical efficacy and safety of nimotuzumab plus chemotherapy in patients with advanced colorectal cancer: a retrospective analysis. Journal of International Medical Research 48:1, pages 030006051989585.
Crossref
Ying Lu, Dagui Chen, Jinhui Liang, Jianquan Gao, Zhanxiong Luo, Rensheng Wang, Wenqi Liu, Changjie Huang, Xuejian Ning, Meilian Liu & Haixin Huang. (2019) Administration of nimotuzumab combined with cisplatin plus 5-fluorouracil as induction therapy improves treatment response and tolerance in patients with locally advanced nasopharyngeal carcinoma receiving concurrent radiochemotherapy: a multicenter randomized controlled study. BMC Cancer 19:1.
Crossref
Xiang-Yun Kong, Jian-Xun Lu, Xin-Wen Yu, Jian Zhang, Qian-Lan Xu, Rong-Jun Zhang, Jing-Lin Mi, Shu-Fang Liao, Jin-Fang Fan, Xiao-Li Qin, Da-Cheng Yao, Hua-Ying Tang & Wei Jiang. (2019) Gemcitabine plus cisplatin versus fluorouracil plus cisplatin as a first-line concurrent chemotherapy regimen in nasopharyngeal carcinoma: a prospective, multi-institution, randomized controlled phase II study. Cancer Chemotherapy and Pharmacology 84:1, pages 155-161.
Crossref
Shuai Zhang, Xiaopeng huang, Liya Zhou & Shaomin Lin. (2018) Efficacy of concurrent chemoradiotherapy combined with nimotuzumab for low-risk T4 stage nasopharyngeal carcinoma. Medicine 97:38, pages e12503.
Crossref
. (2018) Nimotuzumab. Reactions Weekly 1684:1, pages 191-191.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.